<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01693315</url>
  </required_header>
  <id_info>
    <org_study_id>AMA0076-201</org_study_id>
    <nct_id>NCT01693315</nct_id>
  </id_info>
  <brief_title>Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma</brief_title>
  <official_title>A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amakem, NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amakem, NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this dose-escalation study is to evaluate the safety, tolerability and
      efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension
      or primary open-angle glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure change from baseline.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events as a measure of safety/tolerability</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP assessments at weekly visits</measure>
    <time_frame>Weeks 1, 2, 3, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Eye Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - AMA0076 Dose A (or vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: AMA0076 Dose B (or vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: AMA0076 Dose C (or vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: AMA0076 Dose D (or vehicle)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMA0076</intervention_name>
    <arm_group_label>Cohort 1 - AMA0076 Dose A (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 2: AMA0076 Dose B (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 3: AMA0076 Dose C (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 4: AMA0076 Dose D (or vehicle)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1 - AMA0076 Dose A (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 2: AMA0076 Dose B (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 3: AMA0076 Dose C (or vehicle)</arm_group_label>
    <arm_group_label>Cohort 4: AMA0076 Dose D (or vehicle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          1. Adults 30-85 years of age

          2. Diagnosis of either ocular hypertension or primary open-angle glaucoma in both eyes

          3. Not receiving medication for IOP, or able to stop such medication for a washout period
             and the duration of the study without significant risk of adverse consequences related
             to glaucomatous disease

          4. Elevated IOP (≥ 24 and ≤ 34 mm Hg at 8 AM and ≥ 21 and ≤ 34 mm Hg at 10 AM on
             Screening Two visit and Baseline visit in one or both eyes off treatment

        Exclusion Criteria include:

          1. Uncontrolled intraocular hypertension defined as &gt;34 mm Hg at either of the
             screening/baseline visits (after a washout phase in those subjects who were currently
             receiving ocular hypotensive therapy).

          2. Receiving more than one medication for IOP at time of screening.

          3. Central corneal thickness of less than 500 µm or greater than 620 µm.

          4. BCVA worse than 20/200 in either eye

          5. Significant visual field loss (ie, mean deviation &gt; 10 db or field loss within 10
             degrees of fixation), a new field defect, or progression of an existing field defect
             in either eye during the year preceding the study.

          6. Acute angle-closure glaucoma or appositional or very narrow anterior chamber angle in
             either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Artesia Clinical Site - Site 02</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inglewood Clinical Site - Site 03</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petaluma Clinical Site - Site 05</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Haven Clinical Site - Site 01</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Clinical Site - Site 04</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Point Clinical Site - Site 06</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2012</study_first_submitted>
  <study_first_submitted_qc>September 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2012</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

